Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas

Inclusion Criteria: * Written informed consent * Age\>=18 and \<=70years old * Histological diagnosis of malignant gliomas(WHO III or IV) * The status of methylation of promotor of MGMT should be detected. * The time to be enrolled should be more than 90 days after the irradiation. * The patients with recurrent gliomas were treated with non-dose-dense TMZ therapy before enrollment. * Performance status(Karnofsky index)\>=60 * Life expectancy more than 3 months Exclusion Criteria: * Ages:\< 18 years or \> 70 years * Abnormal function of liver or renal(value more than 1.5 fold normal upper limit ) * Blood routing: Hb \< 100g/l， WBC \< 4.0×109/l; PLT \< 100×109/l * Pregnant or lactating women * Allergic to administered drugs * Radiation treatment in the previous 90 days or stereotactic radiation surgery within 60 days before enrollment * The patients with recurrent gliomas were treated with dose-dense TMZ therapy before enrollment. * Life expectancy less than 3 months * Participation in other clinical trials in the 90previous days before enrollment